Reading a preclinical wound-healing model and its relevance to a human tendon posts 91–120

The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well characterised.

If that is already documented somewhere, ignore me and link it.

Useful. I had the fact and not the reason, which turns out to be the important half.

I had written a reply contradicting post #103 and deleted it. Here is what survived.

Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.

It is worth stating the boring hypothesis before the interesting one.

Confirming post #107 from a second method, which matters more than confirming it from a second person.

The lyophilised cake is worth looking at before adding diluent. A collapsed or shrunken cake is not a purity finding but it does say something about how the vial was made and how it travelled.

I would put moderate confidence on the mainstream reading of reading a preclinical wound-healing model and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.

Taking post #107 at face value and following it one step further.

The question underneath reading a preclinical wound-healing model is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.

Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.

Reported local reactions are common enough in first-hand accounts here to be worth mentioning and are not characterised in any published series.

Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.

Confirming post #110 from a second method, which matters more than confirming it from a second person.

The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.

I had written a reply contradicting post #112 and deleted it. Here is what survived.

Reading a preclinical wound-healing model: the model shows whether a mechanism is plausible in a specific context. It does not show magnitude of effect in humans, does not show safety profile in humans, and does not show whether the effect survives in a more complex biological system. That is not a criticism of preclinical work — it is what preclinical work is for.

It reads as pedantry until the day it does not.

BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a dismissal — it is the state of the literature, and any discussion that starts elsewhere is starting from something that is not there.

It is a small point and it changes the answer, which is an awkward combination.

Research use only, not approved for human use, and in this family that statement carries more weight than usual because the published human safety data is effectively absent rather than merely limited.

Somebody will have a better source than mine, and I hope they post it.

The honest answer on reading a preclinical wound-healing model is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much they matter.

Most people get the first two right and then argue about the fourth.

Coming back to post #116, because the follow-up matters more than the original answer.

The lyophilised cake is worth looking at before adding diluent. A collapsed or shrunken cake is not a purity finding but it does say something about how the vial was made and how it travelled.

Taking post #118 at face value and following it one step further.

Worth stating the null on reading a preclinical wound-healing model before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.

Anecdote is the whole of the human evidence base here, and this community's convention is to say so rather than to aggregate anecdotes into something that sounds like data.

That is my reading. Someone else read the same page differently and was reasonable.